CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 87 enrolled
Drug / intervention
Methoxy polyethylene glycol-epoetin betadrug
Likely dose
Methoxy polyethylene glycol-epoetin beta 250 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01519947
NCT01519947Phase 4Completed

Comparative Study to Evaluate the Effect of the Altitude on Dosage Requirements of Methoxy Polyethylene Glycol-Epoetin Beta to Correct Hemoglobin Levels in Chronic Renal Anemia in Pre-Dialysis and Dialysis Patients

Hoffmann-La Roche·interventional·Posted Jan 27, 2012·Updated Jun 19, 2019

In Brief

A Phase 4 clinical trial evaluating Methoxy polyethylene glycol-epoetin beta for Anemia, Kidney Disease, Chronic. Completed, enrolled 87 participants across 7 sites.

Detailed Summary

This comparative, open-label, multicenter, parallel-group study evaluated the effect of altitude on the dose requirements of Mircera (methoxy polyethylene glycol-epoetin beta) to achieve a target hemoglobin concentration of 11-12 grams per deciliter (g/dL) in participants with chronic renal anemia in pre-dialysis and dialysis. Four groups of participants, at sea level (below 50 meters) or an altitude above 1800 meters, and pre-dialysis or dialysis, received 50-250 micrograms (mcg) Mircera subcutaneously (SC), according to the local prescribing label.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesMexico
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 27, 2012
Enrollment StartMay 30, 2012
Primary CompletionMay 30, 2015
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 14.4 years ago

Interventions

Methoxy polyethylene glycol-epoetin betadrug

Participants received 50-250 mcg SC according to local label